TY - JOUR
T1 - Establishment of Monoclonal Antibody PMab-202 Against Horse Podoplanin
AU - Furusawa, Yoshikazu
AU - Yamada, Shinji
AU - Itai, Shunsuke
AU - Sano, Masato
AU - Nakamura, Takuro
AU - Yanaka, Miyuki
AU - Handa, Saori
AU - Mizuno, Takuya
AU - Maeda, Ken
AU - Fukui, Masato
AU - Harada, Hiroyuki
AU - Kaneko, Mika K.
AU - Kato, Yukinari
N1 - Funding Information:
We thank Kayo Hisamatsu and Yoshimi Nakamura for excellent technical assistance. This research was supported in part by AMED under grant numbers JP18am0101078 (Y.K.), JP18am0301010 (Y.K.), and JP18ae0101028 (Y.K.), and by JSPS KAKENHI grant numbers 17K07299 (M.K.K.) and 16K10748 (Y.K.).
Publisher Copyright:
© Copyright 2018, Mary Ann Liebert, Inc., publishers 2018.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/11
Y1 - 2018/11
N2 - Podoplanin (PDPN), a type I transmembrane glycoprotein, is expressed in several body tissues, including podocytes of renal glomerulus, type I alveolar cells of lung, and lymphatic endothelial cells. PDPN activates platelet aggregation by binding to C-type lectin-like receptor-2 (CLEC-2) presented on platelets. Monoclonal antibodies (mAbs) against human-, mouse-, rat-, rabbit-, dog-, bovine-, and cat-PDPN have already been established. However, anti-horse PDPN mAbs have not yet been developed. In this study, we immunized mice with synthetic horse PDPN peptides and developed anti-horse PDPN mAbs. One of the established mAbs, PMab-202 (IgG1, kappa), was specifically able to detect horse PDPN in Chinese hamster ovary/horse PDPN (CHO/horPDPN) cells in flow cytometry experiments. PMab-202 was also able to detect endogenous horse PDPN expressed in and a horse kidney cell line, FHK-Tcl3.1, in flow cytometry and Western blot analyses. PMab-202 is expected to prove useful in investigating the function of horse PDPN.
AB - Podoplanin (PDPN), a type I transmembrane glycoprotein, is expressed in several body tissues, including podocytes of renal glomerulus, type I alveolar cells of lung, and lymphatic endothelial cells. PDPN activates platelet aggregation by binding to C-type lectin-like receptor-2 (CLEC-2) presented on platelets. Monoclonal antibodies (mAbs) against human-, mouse-, rat-, rabbit-, dog-, bovine-, and cat-PDPN have already been established. However, anti-horse PDPN mAbs have not yet been developed. In this study, we immunized mice with synthetic horse PDPN peptides and developed anti-horse PDPN mAbs. One of the established mAbs, PMab-202 (IgG1, kappa), was specifically able to detect horse PDPN in Chinese hamster ovary/horse PDPN (CHO/horPDPN) cells in flow cytometry experiments. PMab-202 was also able to detect endogenous horse PDPN expressed in and a horse kidney cell line, FHK-Tcl3.1, in flow cytometry and Western blot analyses. PMab-202 is expected to prove useful in investigating the function of horse PDPN.
KW - PDPN
KW - PMab-202
KW - horse podoplanin
UR - http://www.scopus.com/inward/record.url?scp=85055613418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055613418&partnerID=8YFLogxK
U2 - 10.1089/mab.2018.0030
DO - 10.1089/mab.2018.0030
M3 - Article
C2 - 30362932
AN - SCOPUS:85055613418
SN - 2167-9436
VL - 37
SP - 233
EP - 237
JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
IS - 5
ER -